Tartu University Hospital
- Address
- 167 Riia Street, 51014 Tartu, Estonia
Tartu University Hospital - Infectious Disease Prevention Research
Tartu University Hospital is a leading medical research institution in Estonia with specialized expertise in vaccine development and immunogenicity studies. The center plays a vital role in international clinical research, particularly in the evaluation of preventive interventions for infectious diseases in older adult populations.
- Phase 3 influenza vaccine trials in elderly populations aged 60 years and above
- Immunogenicity assessment and comparative vaccine effectiveness studies
- Safety evaluation of high-dose vaccine formulations for vulnerable populations
The hospital demonstrates particular strength in conducting noninferiority studies that compare novel vaccine candidates against established reference products. Their research contributes to advancing protection strategies for older adults who are at increased risk for severe influenza complications, focusing on optimizing immune responses through enhanced vaccine formulations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 44 other sites in Estonia
Therapeutic Area Benchmark — Estonia
Select a therapeutic area to compare against other sites in Estonia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Estonia
Market Share
Country: Estonia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Tartu University Hospital
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase III Randomized, Observer-Blind Study on Safety and Immunogenicity of High-Dose Trivalent Influenza Vaccine in Adults Aged 60 and Above | Abbott Biologicals B.V. | Phase III | Not Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238) | 1 | Unknown | 2025-10-20 | 2025-10-20 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.